CAS: 5121-34-6; Methyl 2-Amino-3-Methoxybenzoate

上下游产品

CAS号3177-80-8 2-氨基-3-甲氧基苯甲酸 | CAS号5307-17-5 3-甲氧基-2-硝基苯甲酸甲酯 | CAS号67-56-1 甲醇 | CAS号34954-65-9 3-甲氧基靛红酸酐 | CAS号80-11-5 N-甲基-N-亚硝基对甲苯磺酰胺 | CAS号186581-53-3 重氮甲烷 | CAS号33768-49-9 N-(pivaloyl)ort... | CAS号90-04-0 邻氨基苯甲醚 | CAS号5368-81-0 3-甲氧基苯甲酸甲酯 | CAS号115378-20-6 3-methoxy-2-piv... | CAS号33234-36-5 2-氯-3-甲氧基苯甲酸 | CAS号194782-60-0 Benzenamine,2-m... | CAS号214476-78-5 4-氯-8-甲氧基喹啉-3-甲腈 | CAS号71083-71-1 1,4-二氢-8-甲氧基-4-... | CAS号5081-17-4 2-amino-3-metho... | CAS号59425-26-2 methyl 2-chloro... | CAS号51786-10-8 2-氯-3-羟基苯甲酸 | CAS号61535-31-7 2-chloro-3-phen... | CAS号61535-32-8 2-chloro-3-phen...

3-羟基-2-硝基苯甲酸置于palladium 10% On Activated Carbon,氢气,Potassium Carbonate体系中,用 甲醇,N,N-二甲基甲酰胺 作为反应溶剂,20.0 °C,413.7 Kpa 条件下,反应 2.0H,反应生成 2-氨基-3-甲氧基苯甲酸甲酯
参考文献: Quinazolines And Azaquinazolines As Dual Inhibitors Of Ras/raf/mek/erk And Pi3K/akt/pten/mtor Pathways[fr] Quinazolines Et Azaquinazolines En Tant Que Doubles Inhibiteurs Des Voies Ras/raf/mek/erk Et Pi3K/akt/pten/mtor
标题: Quinazolines And Azaquinazolines As Dual Inhibitors Of Ras/raf/mek/erk And Pi3K/akt/pten/mtor Pathways[fr] Quinazolines Et Azaquinazolines En Tant Que Doubles Inhibiteurs Des Voies Ras/raf/mek/erk Et Pi3K/akt/pten/mtor
摘要:本申请提供了新型喹唑啉和氮杂喹唑啉及其药用可接受盐.还提供了制备这些化合物的方法.通过向患者投与式有效量的式(I)化合物中的一个或多个,其中x,Y,T和r4,以及r6到r8'在此处定义,来共同调节ras/raf/mek/erk和pi3K/akt/pten/mtor途径.通过这样做,这些化合物在治疗与ras/raf/mek/erk和pi3K/akt/pten/mtor途径失调相关的疾病方面是有效的.可以使用这些化合物治疗各种疾病,包括以异常细胞增殖为特征的疾病.在一个实施例中,该疾病是癌症.

专利信息

专利号:US-10889574-B2
优先权日:2016-06-17
标 题 :Method for producing diphenylmethane derivative
发明人：YOON HEE-KYOON; PARK SE-HWAN; YOON JI-SUNG; CHOI SOONGYU; SEO HEE JEONG; PARK EUN-JUNG; KONG YOUNGGYU; SONG KWANG-SEOP; KIM MIN JU; PARK SO OK
权利人:DAE WOONG PHARMA; GREEN CROSS CORP
摘要:The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.